Executive Summary
Key findings
Prescription pharmaceuticals sales and growth rate analysis, 2003–15
Operating costs and profit analysis
Shionogi: PharmaVitae forecasts at a glance
Strategic insight
Focus on "core strategic" product lines
Late-stage pipeline productsShionogi’s launch portfolio consists of 10 products, six of which have already come to market – Cymbalta, Pirespa (pirfenidone), Rapiacta (peramivir), Kapvay (clonidine hydrochloride), and Cuvposa (glycopyrrolate) – indicating its success in launching late-stage products. Furthermore, over 2009–15, Shionogi plans to file New Drug Applications (NDAs) for at least four late-stage pipeline products (S-349572, S-474474, Ospemifene, and PSD502), and potentially more products if possible.
Global expansion
CNS, ID and CV focus
Decreased emphasis on non-pharmaceuticals business
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structureExecutive summary
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Key findings
Latest quarterly sales
Q4 2009Shionogi: rapid Japanese approval represents important milestone for peramivir
Q2 2009
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q3 2010
Q2 2009
Q1 2009
Q4 2009
Q3 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A historyShionogi and Eli Lilly capsule business
[Missing title]
Current corporate structure
PharmaceuticalsShionogi is primarily focused on its pharmaceuticals business, which accounts for more than 90% of its total net sales. Crestor (rosuvastatin) is a key contributing product to Shionogi’s pharmaceuticals segment. A "superstatin", Crestor, was developed in-house by Shionogi and then out-licensed to AstraZeneca in 1998. AstraZeneca has worldwide marketing exclusivity, except in Japan where the product is co-promoted by the two companies.
Consumer health Shionogi has a small consumer health division, which concerns itself predominantly with the sale of OTC products. These are generally analgesics, antipyretics, vitamins, and minerals. Key products include: the Sedes range‚ a brand of analgesics; Pylon‚ a cold remedy brand; and Popon‚ a family of vitamin compounds. Shionogi has recently expanded its Popon brand‚ adding new formulations to the line. Popon B (muscle fatigue) and Popon Pumeri (eye fatigue) were launched in 2009. In addition to OTC medications‚ Shionogi also markets the Correct brand of denture products.
Diagnostics
COMPANY SALES
Key findings
Prescription pharmaceuticals sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key findings
Overview
Cardiovascular
[Missing title]
Irbetan
Central nervous system
[Missing title]
Infectious disease
Flomox
S-349572
APPENDIX
References
Abbreviations
Exchange rates
[Inhaltsverzeichnis ausblenden]
